- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Recent Trends and Innovations in the Management of CLL
Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.
EP: 1.Recent Trends and Innovations in the Management of CLL
EP: 2.CLL Treatment Landscape: Overview of BTK Inhibitors
EP: 3.Evaluating Value of BTK Inhibitors in CLL Treatment
EP: 4.Factors Influencing Choice of Second-Generation BTKi Monotherapy
EP: 5.Empowering Patients: Key Considerations for BTK Inhibitor Adherence
EP: 6.Optimizing Therapy Sequencing in CLL
EP: 7.Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
EP: 8.Decision-Making in CLL: The Role of Real-World Evidence
EP: 9.Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment
EP: 10.Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization
EP: 11.Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers
EP: 12.The Inflation Reduction Act: Implications for Patient Access in CL
EP: 13.Patient Access Advocacy for BTK Inhibitors
EP: 14.Future Directions of BTK Inhibitors in Leukemia and Lymphoma
Video content above is prompted by the following questions:
- How has the story of CLL treatment evolved in recent history? What are the latest trends and innovations you have observed in the treatment and management of CLL leading up to ASCO 2024?
- Coming into ASCO 2024, what would you consider to be the largest unmet needs in the treatment and management of CLL?
Infection Rate More Than Double in CLL/SLL Accompanied By Secondary Immunodeficiency Disease
December 19th 2024Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Read More
6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL
December 10th 2024Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.
Read More
